title: Effect of administration and subsequent cessation of buserelin on cancellous bone of female rats.
abstract: Although hormone replacement therapy is effective in preventing postmenopausal bone loss, it fails to cause a return of bone mass to normal in patients with established osteoporosis. Similarly, in the ovariectomized rat, estrogen administration protects the skeleton from bone loss but fails to reverse this once it has occurred. However, physiologically produced sex steroids may, in contrast to conventional methods of sex steroid administration, be capable of restoring bone mass in osteopenic states. To investigate this question, we analyzed the effect of treatment with the LHRH agonist buserelin for varying durations, and subsequent cessation thereof, on histomorphometric indices of rat cancellous bone. Female rats 13 weeks old were given daily SC injections of vehicle or buserelin as follows: vehicle days 1-90; vehicle days 1-150; vehicle days 1-60, buserelin days 61-90; vehicle days 1-60, buserelin days 61-90, vehicle days 91-150; vehicle days 1-30, buserelin days 31-90; vehicle days 1-30, buserelin days 31-90, vehicle days 91-150; buserelin days 1-90; buserelin days 1-90, vehicle days 91-150. At the end of the treatment period, animals were killed, tibiae removed, and histomorphometric indices assessed at the secondary spongiosa of the proximal metaphysis. Analysis of vaginal smears confirmed that buserelin rapidly suppressed ovulation, which quickly returned once treatment was stopped. We found that administration of buserelin for 30, 60, or 90 days reduced cancellous bone volume because of a reduction in both the number and thickness of trabeculae.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Histopathology, St. George's Hospital Medical School, London, England.
authors.forename: J H
authors.initials: JH
authors.lastname: Tobias
authors.forename: T J
authors.initials: TJ
authors.lastname: Chambers
authors.forename: A
authors.initials: A
authors.lastname: Gallagher
mesh_terms: D000818:Animals; D001846:Bone Development / Q000187:drug effects*; D001862:Bone Resorption; D002064:Buserelin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004958:Estradiol / Q000097:blood; D005260:Female; D007279:Injections, Subcutaneous; D009929:Organ Size / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects*; D011374:Progesterone / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D013977:Tibia / Q000187:drug effects* / Q000502:physiology; D013997:Time Factors; D014599:Uterus / Q000033:anatomy & histology / Q000187:drug effects
chemical_list: D011374:Progesterone; D004958:Estradiol; D002064:Buserelin